Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease
ABSTRACT Objective Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.
Tuhin Virmani +8 more
wiley +1 more source
Scoping review: Intervention for ocular motor disorders in children and adults with mild traumatic brain injury. [PDF]
Chen AM +8 more
europepmc +1 more source
The impact of lockdown on Functional Motor Disorders patients during the first COVID-19 outbreak: acase-control study. [PDF]
Di Vico IA +6 more
europepmc +1 more source
ABSTRACT Objective Accurate localization of epileptogenic tubers (ETs) in patients with tuberous sclerosis complex (TSC) is essential but challenging, as these tubers lack distinct pathological or genetic markers to differentiate them from other cortical tubers.
Tinghong Liu +11 more
wiley +1 more source
White matter lesions contribute to motor and non-motor disorders in Parkinson's disease: a critical review. [PDF]
Jiang YQ +11 more
europepmc +1 more source
Economic Costs of Delayed Diagnosis of Functional Motor Disorders: Preliminary Results From a Cohort of Patients of a Specialized Clinic. [PDF]
Tinazzi M +3 more
europepmc +1 more source
Life‐Threatening Bradycardia in Anti‐NMDA‐Receptor Encephalitis and a Novel Use for Permanent Pacing
ABSTRACT Background Pediatric anti‐NMDA receptor encephalitis (pNMDARE) is an autoantibody‐mediated disorder that can cause severe autonomic dysfunction, including symptomatic bradycardia and asystole. Dysautonomia can last for years, making it very challenging to manage.
Sarah Tucker +9 more
wiley +1 more source
Wavelet-Detected Changes in Nocturnal Brain Electrical Activity in Patients with Non-Motor Disorders Indicative of Parkinson's Disease. [PDF]
Runnova AE +5 more
europepmc +1 more source
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
How to Help Deaf Children Who Do Not Understand Their Vestibular Symptoms and Motor Disorders as Abnormal? [PDF]
Melo RS.
europepmc +1 more source

